Dual eligibles cost federal and state governments approximately $120 billion a year.
Dual eligibles cost federal and state governments approximately $120 billion a year.
Proposals for controlling these outlays involve coordination of Medicare and Medicaid payment and coverage policies. Although about 70% of Medicaid beneficiaries are in some kind of managed care arrangement, most Medicaid plans exclude dual eligibles and long-term care. Differences in Medicare and Medicaid reimbursement stymies care coordination and encourages churning.
Consequently, less than 2% of all dual eligibles are in a coordinated care program, according to report from the Medicare Payment Advisory Commission (MedPAC) released in June. SNPs grew initially, but Congress stopped enrollment a few years ago due to concerns the plans were skimping on specialized care needed for duals.
Now policy makers are looking for new coordinated care strategies. Legislation enacted in 2008 requires all new D-SNPs to contract with a state Medicaid agency by the end of next year, and MedPAC proposes applying that policy to all D-SNPs.
The Federal Coordinated Healthcare Office (FCHCO), authorized by the Patient Protection and Affordable Care Act (PPACA), seeks to better align federal and state programs by reducing differences in fee-for-service benefits, prescription drug coverage, cost-sharing, enrollment processes and appeals. The Centers for Medicare and Medicaid Services (CMS) recently proposed to test a new prospective payment model for comprehensive care by health plans and states, plus a shared savings arrangement with state-managed FFS initiatives, FCHCO Director Melanie Bella told the House subcommittee at a June hearing.
SOLUTIONS FOR DUAL POPULATION
The Center for Medicare and Medicaid Innovation, also created by PPACA, is piloting care coordination for dual eligibles by state agencies that assume risk for providing full benefits. CMS has awarded contracts worth up to $1 million each to 15 states.
Similarly, the Association of Community Affiliated Plans and Medicaid Health Plans of America are promoting strategies to reduce costs by transitioning dual eligibles into fully integrated, capitated programs. Some legislators want to extend Medicaid drug rebates to Medicare drug plans serving dual eligibles, which would yield an estimated $50 billion in annual savings.
MedPAC plans to explore whether automatic enrollment can help increase SNP participation. Care coordination can occur within FFS Medicare, but MedPAC believes that capitated, risk-based integrated programs can more effectively coordinate acute and long-term services.
Jill Wechsler, a veteran reporter, has been covering Capitol Hill since 1994.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More